G Sanna, G Petralia, M Cossu Rocca, C Marenghi, F Nolè
Department of Medicine, Unit for Medical Care, European Institute of Oncology.
Clin Med Oncol. 2008;2:103-8. doi: 10.4137/cmo.s317. Epub 2008 Feb 9.
The incidence of brain metastases (BMs) is apparently rising in patients with advanced breast cancer, possibly due to better therapeutic approaches for control of metastatic growth in other organs. Occurrence of BMs severely affects quality of life and is associated with dire prognosis. In this short report we describe the clinical case of a 47 year old woman, with BMs from breast cancer diagnosed in May 2001. The patient was treated with whole brain irradiation and radiosurgery, with initial control of BMs. Due to previous radiotherapy fields and doses, further local treatments are not feasible anymore. Since September 2006, the patient has been receiving systemic therapy with Lapatinib at the dose of 1500 mg/die continuously, with a good control of cerebral, liver and nodal metastasis after one year of treatment (September 2007). Her quality of life is acceptable, her Karnofsky Performance Status (KPS) is more than 70%, and she takes care of her family, and has not experienced neuro-cognitive dysfunction.
晚期乳腺癌患者脑转移(BMs)的发生率明显上升,这可能归因于对其他器官转移生长的控制有了更好的治疗方法。脑转移的发生严重影响生活质量,并与预后不良相关。在本简短报告中,我们描述了一名47岁女性的临床病例,她于2001年5月被诊断为乳腺癌脑转移。患者接受了全脑照射和放射外科治疗,脑转移最初得到控制。由于先前的放疗范围和剂量,进一步的局部治疗已不再可行。自2006年9月以来,患者一直在接受拉帕替尼全身治疗,剂量为1500毫克/天,持续用药,治疗一年后(2007年9月),脑、肝和淋巴结转移得到良好控制。她的生活质量尚可接受,卡诺夫斯基功能状态评分(KPS)超过70%,她能照顾家人,且未出现神经认知功能障碍。